--- title: Understanding Cannabinoid Degradation Pathways description: How do we understand the Cannabinoid Degradation Pathways image: https://www.broughton-group.com/hubfs/iStock-1384444046.jpg --- # Understanding Cannabinoid Degradation Pathways ### Cannabinoids ![](https://www.broughton-group.com/hubfs/iStock-1384444046.jpg) Dec 13, 2024 | Published by  [ Broughton ](https://www.broughton-group.com/blog/author/broughton) Cannabinoids The stability of cannabinoid products is a critical factor for manufacturers aiming to deliver high-quality, safe, and effective products. Cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), are naturally occurring compounds in *Cannabis sativa* known for their therapeutic potential. However, these compounds are inherently unstable and prone to degradation under various environmental conditions, which can significantly impact product quality, efficacy, and safety. **What Causes Cannabinoid Degradation?** Cannabinoids degrade through several pathways influenced by environmental factors: 1. **Light Exposure**: Ultraviolet (UV) light can accelerate the breakdown of cannabinoids. For example, THC degrades into cannabinol (CBN), a less psychoactive compound, when exposed to light. 2. **Heat**: Elevated temperatures can cause cannabinoids to decarboxylate and degrade further, particularly during storage or in high-heat delivery systems like vaping. 3. **Oxidation**: Oxygen exposure triggers oxidative reactions that alter the chemical structure of cannabinoids, resulting in decreased potency and potential formation of unwanted by-products. 4. **pH Variations**: Acidic or basic environments can catalyse degradation reactions, particularly for CBD, which can convert to THC under certain conditions. **The Impacts of Degradation** Degradation affects cannabinoid products in several ways: - **Reduced Efficacy**: The active compounds responsible for therapeutic benefits may degrade, reducing the product’s effectiveness. - **Toxicological Risks**: Breakdown products may have unknown or harmful effects on consumers. For example, the formation of cannabinoid quinones can pose safety concerns. - **Legal and Regulatory Issues**: Degradation can lead to the formation of controlled substances like THC from CBD, creating compliance challenges for manufacturers. **Strategies to Mitigate Degradation** Understanding and mitigating degradation pathways is essential for maintaining product integrity. Manufacturers can adopt several strategies to protect cannabinoids: - **Optimised Packaging**: Use materials that block light and have low oxygen permeability to reduce exposure to degradation triggers. - **Controlled Storage Conditions**: Maintain appropriate temperature and humidity levels to minimise thermal and oxidative stress. - **Stability-Indicating Methods**: Implement advanced analytical techniques to monitor degradation products and ensure regulatory compliance. **Conclusion** Cannabinoid degradation is a complex process influenced by various environmental factors and product formulations. For manufacturers, understanding these pathways is vital to delivering products that meet safety, efficacy, and regulatory standards. Through robust stability studies and proactive measures, the risks of cannabinoid degradation can be effectively managed, ensuring product quality and consumer trust. If you’d like expert support in assessing and mitigating cannabinoid degradation, Broughton’s team of specialists can provide comprehensive stability testing and consultancy services. [Download our whitepaper to learn more about safeguarding your cannabinoid products.](https://www.broughton-group.com/lp-degradation-pathways-of-cannabinoids) ### Sign up to our newsletter Ensure your business stays ahead of the competition by keeping up to date with the latest industry news. Sign-up for our newsletter to have the latest information and insights served directly to your inbox. ### Related posts [View all](https://www.broughton-group.com/blog/) [![](https://www.broughton-group.com/hs-fs/hubfs/iStock-1369377470%20mushrooms.jpg?height=200&name=iStock-1369377470%20mushrooms.jpg) ](https://www.broughton-group.com/blog/emerging-pharmaceutical-sectors-to-watch-in-2023-pyschedelics) [**Pharmaceuticals**](https://www.broughton-group.com/blog/tag/pharmaceuticals) 2 minute read ### [Emerging pharmaceutical sectors to watch in 2023: Pyschedelics](https://www.broughton-group.com/blog/emerging-pharmaceutical-sectors-to-watch-in-2023-pyschedelics) Broughton CEO, Chris Allen, looks at the emerging field of psychedelic pharmaceutical drug development and shares some of the best articles he read in 2022. [![](https://www.broughton-group.com/hubfs/1738111659848.jfif) ](https://www.broughton-group.com/blog/takeaways-from-the-keller-heckmann-e-vapor-and-tobacco-law-symposium) [**Nicotine**](https://www.broughton-group.com/blog/tag/nicotine) 2 minute read ### [Takeaways from the Keller & Heckman E-Vapor and Tobacco Law Symposium](https://www.broughton-group.com/blog/takeaways-from-the-keller-heckmann-e-vapor-and-tobacco-law-symposium) The Keller and Heckman LLP E-Vapor and Tobacco Law Symposium provided in-depth discussions on the regulatory landscape, the evolving challenges faced by the industry, and the potential changes ahead.... [![](https://www.broughton-group.com/hs-fs/hubfs/ENDS.png?height=200&name=ENDS.png) ](https://www.broughton-group.com/blog/ends-europe-conference) [**Nicotine**](https://www.broughton-group.com/blog/tag/nicotine) 2 minute read ### [ENDS Europe Conference](https://www.broughton-group.com/blog/ends-europe-conference) Broughton’s Managing Consultant for Product Realization, Pete Lomas, shares his thoughts from the recent ENDS (Electronic Nicotine Delivery System) Europe Conference held in Amsterdam.